BAXFENDY Becomes the First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension
AstraZeneca’s BAXFENDY (baxdrostat) has received US approval as the first aldosterone synthase inhibitor (ASI) for treating hypertension in adults whose blood pressure remains uncontrolled despite the use of other antihypertensive therapies.
Hypertension affects nearly 1.4 billion individuals globally. In the US, about half of hypertension patients already taking multiple blood pressure medications continue to experience uncontrolled hypertension, a major contributor to cardiovascular disease and early mortality. Hypertension remains the most common and impactful ...